Targeting IL-6-STAT3/STAT4 Signaling Restores FOXP3 Expression in Pulmonary Arterial Endothelium and Reveals Novel Biomarkers for PAH

作者
Prabhjot Kaur,Katherine Jankowski,Anurupa Ghosh,Carlos G. Santos‐Gallego,Anjira S. Ambade,Tahiris Duran,Yomna El Zibaoui,Marîa Teresa Ochoa,Maryam Mansoori,Hooman D. Poor,Yassine Sassi,Paul M. Hassoun,Malik Bisserier,Lahouaria Hadri
出处
期刊: [Cold Spring Harbor Laboratory]
标识
DOI:10.64898/2026.04.29.721729
摘要

ABSTRACT Background Interleukin-6 (IL-6) is a central driver of pulmonary vascular remodeling in idiopathic, heritable, and connective tissue disease-associated pulmonary arterial hypertension (PAH). Elevated IL-6 correlates with right ventricular (RV) dysfunction and poor survival. However, the specific downstream mechanisms by which IL-6 drives pathogenesis remain poorly defined. We investigated the therapeutic impact of direct IL-6 neutralization and its regulation of a novel epigenetic signaling axis in PAH. Materials and Methods We evaluated species-specific IL-6-neutralizing antibodies in murine Sugen/hypoxia and rat monocrotaline models of PAH. RV structure and function were assessed using cardiac MRI and invasive hemodynamics. Lung transcriptomic profiling was performed by RNA sequencing mouse lung tissue. Key findings were validated in explanted human PAH lungs, serum, and peripheral blood mononuclear cells (PBMCs), and further interrogated through mechanistic in vitro studies in human pulmonary artery endothelial cells (PAECs). Results IL-6 neutralization significantly improved RV function, reduced pulmonary arterial pressures, and attenuated pulmonary vascular remodeling in both experimental models. Transcriptomic analysis identified a dysregulated FOXP3 signaling axis. Mechanistically, IL-6 induced cooperative binding of phosphorylated STAT3 and STAT4 to the FOXP3 promoter, facilitating DNMT1-mediated DNA methylation and stable gene silencing. IL-6 blockade restored downstream FOXP3 expression, rescued downstream BMPR2 signaling, and re-established endothelial homeostasis. In clinical PAH cohorts, FOXP3 expression was markedly reduced and inversely correlated with circulating IL-6 levels and indices of disease severity. Conclusion IL-6 drives pulmonary hypertension through STAT3/STAT4- and DNMT1-dependent epigenetic repression of FOXP3, linking chronic inflammation to BMPR2 dysfunction and pulmonary vascular remodeling. IL-6 neutralization reverses this pathogenic program in experimental PAH. FOXP3 emerges as a mechanistic biomarker of disease severity and a potential tool for precision stratification of patients likely to benefit from IL-6-targeted therapies. Clinical Perspective What Is New? Synergistic Gene Repression: The study demonstrates that phosphorylated STAT3 functional transcriptional complex that binds directly to the FOXP3 promoter. Acting as a molecular scaffold, this complex actively represses FOXP3 expression within the pulmonary endothelium. Epigenetic Silencing Mechanism: IL-6 does not merely induce a transient suppression of FOXP3. Instead, IL-6/STAT3 signaling recruits DNMT1 to the FOXP3 promoter, leading to site-specific DNA methylation and long-term epigenetic silencing. This mechanism provides a direct molecular link between chronic systemic inflammation and sustained pulmonary vascular injury. The FOXP3-BMPR2 Connection: The findings identify FOXP3 as a critical positive regulator of BMPR2 expression. Neutralization of IL-6 disrupts this pathological inhibitory loop, permitting restoration of BMPR2 signaling, the central gatekeeper of pulmonary vascular integrity and homeostasis. Translational Biomarkers: Importantly, the molecular changes within the lung are reflected systemically. Suppressed FOXP3 expression is readily detectable in PBMCs and serum, offering a non-invasive biomarker that correlates with pulmonary hemodynamic status and vascular health. Clinical Implications Precision Patient Stratification: FOXP3 expression in PBMCs and serum functions as a surrogate marker of pulmonary vascular epigenetic health. This could identify a specific inflammatory endotype of PAH patients most likely to respond to IL-6-targeted therapies. Prognostic Biomarker: Because FOXP3 levels integrate both systemic inflammatory burden and dysfunction of the RV-pulmonary vascular axis, they may provide a more sensitive tool for monitoring therapeutic response and predicting clinical worsening than current standard-of-care markers.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haha完成签到,获得积分10
1秒前
觅海完成签到 ,获得积分10
1秒前
1秒前
干净雪卉完成签到 ,获得积分10
1秒前
2秒前
2秒前
2秒前
冷酷的依瑶的应助被易123采纳,获得10
3秒前
molihuakai的应助被鲸落采纳,获得10
3秒前
秋风的应助被任性的皮卡丘采纳,获得10
3秒前
青歌发布了新的文献求助10
3秒前
炫彩小陈完成签到,获得积分10
3秒前
gzsy完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
陌生人儁发布了新的文献求助10
3秒前
顺利的丹妗完成签到 ,获得积分10
4秒前
4秒前
4秒前
苏西yy发布了新的文献求助10
4秒前
情怀的应助被天天小女孩采纳,获得10
4秒前
xu发布了新的文献求助10
4秒前
星眠完成签到,获得积分10
4秒前
4秒前
碧蓝丹烟完成签到,获得积分10
4秒前
miracle完成签到,获得积分10
4秒前
JamesPei的应助被麦豆腐德采纳,获得10
4秒前
大模型的应助被cbw采纳,获得10
5秒前
小马甲的应助被顺利的莺采纳,获得10
5秒前
风吹麦浪的应助被锂电提桶人采纳,获得10
5秒前
5秒前
5秒前
xiao完成签到,获得积分10
5秒前
5秒前
xinxin完成签到,获得积分10
5秒前
ry发布了新的文献求助30
6秒前
6秒前
科研通AI6.4的应助被cs采纳,获得10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317